Q4 FY2025 · ended Dec 31, 2025 · Revenue $-1.21M · Filed Mar 9, 2026
Sab Biotherapeutics, Inc. (SABS) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$14.4 million. As of Sep 30, 2026 it held $205.3 million in cash and investments and $4.9 million in total debt.
Revenue
$-1.21M
Net income
$-22.30M
-149.1% vs year-ago quarter
Operating cash flow
$-13.02M
+0.2% vs year-ago quarter
Free cash flow
$-14.37M
-25.7% vs prior quarter
EPS
$-0.24
-14.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
90.09M
+89.2% vs year-ago quarter
Net cash
$200.42M
Q3 FY2026
Operating margin
1305.8%
Q4 FY2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SABS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1833214
- Former names
- Big Cypress Acquisition Corp. (until Oct 22, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | -$1.2M | — |
| Operating income | -$25.9M | -$23.4M | -$20.0M | -$15.8M | -$12.7M |
| Net income | -$22.3M | -$22.5M | -$18.9M | -$16.9M | $45.4M |
| Diluted EPS | -$0.24 | -$0.28 | -$0.35 | -$0.02 | -$0.21 |
| Operating cash flow | -$13.0M | -$9.8M | -$14.3M | -$16.8M | -$13.0M |
| Free cash flow | -$14.4M | -$11.4M | -$15.3M | -$17.4M | — |
| Total assets | $235.6M | $238.2M | $248.5M | $172.8M | $183.4M |
| Total liabilities | $24.7M | $23.4M | $21.2M | $21.3M | $18.4M |
| Stockholders' equity | $210.9M | $214.8M | $227.2M | $151.5M | $165.1M |
| Cash and investments | $205.3M | $208.0M | $217.6M | $143.5M | $161.5M |
| Total debt | $4.9M | $5.1M | $6.2M | $6.0M | $6.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 7, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 433 Sab Biotherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.